Embecta (Nasdaq:EMBC) announced a new publication introducing best practices for insulin injection techniques and education.
The publication in the Mayo Clinic Proceedings introduces the FITTER Forward Expert Recommendations. These best practices, authored by a panel of 16 diabetes specialists from 13 countries, highlight the critical need for improved training and standardization in insulin delivery. It aims to enhance clinical outcomes for millions of people with diabetes worldwide.
Standardization remains an important topic in the diabetes technology space. A recent study also indicated the need for more guidelines and standardization in clinical studies of continuous glucose monitor (CGM) technology.
“When physicians and nurses discuss insulin treatments, they usually focus on the specific dose, but not so much on how exactly the insulin is administered. However, proper injection technique, proper handling of injection devices, and proper insulin handling can all significantly improve long-term glycemic control,” said Dr. David Klonoff, medical director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center, Clinical Professor of Medicine at UCSF, and lead author of the publication. “How insulin is injected actually plays a more crucial factor in maintaining target blood glucose levels than many realize. This new recommendation provides healthcare professionals with clear, evidence-based strategies to help ensure that insulin is delivered correctly and safely.”
More about the FITTER recommendations shared by Embecta
The Forum for Injection Technique and Therapy Expert Recommendations (FITTER) initially came about in 2016. Embecta, then the Diabetes business unit of BD, developed it to guide insulin administration best practices.
Since then, the company says advancements in device technology, research and real-world patient data warrant a major update. Embecta seeks new insights on injection device technology, including needle length, pen needle design, width and sharpness. It hopes to optimize patient comfort and correct insulin delivery.
The company also wants to standardize injection techniques and overcome existing gaps. This could help prevent complications like lipodystrophy and inconsistent insulin absorption. Structured training programs for providers would also equip them with practical tools for patient education. Meanwhile, Embecta wanst patient-centered recommendations and tools to help those with diabetes reduce pain, overcome fear-based barriers and improve overall adherence to insulin therapy.
“As a company dedicated to advancing diabetes care for more than 100 years, embecta is proud to support the FITTER Forward initiative,” said Dr. Pasha Javadi, senior director, Global Medical Affairs at Embecta. “Proper injection technique is a fundamental aspect of medicine delivery—whether it’s insulin, GLP-1s, or other injectable therapies. By empowering healthcare professionals with the latest research-backed recommendations, we can help improve patient outcomes and ensure that injection therapy is as effective and comfortable as possible.”
Embecta itself develops a number of insulin delivery devices. The company won FDA approval for a disposable patch pump system in September 2024. It had also long touted a closed-loop automated system under development. However, in November 2024, it discontinued its patch pump program amid rumors of the company exploring a sale, which began circulating in July.
[Embecta compensated Dr. Klonoff for his work on the FITTER Forward initiative.]
